AMENDMENTS TO THE CLAIMS

Please cancel claims 1-16 without prejudice or disclaimer.

Claims 1 - 16. (Canceled)

17. (Original) A method of treatment of a mammal suffering from HIV, a retroviral infection genetically related to HIV, or AIDS which comprises treating said mammal with a therapeutically effective amount of one or more agents capable of inhibiting protein isoprenylation, or a pharmaceutically acceptable salt, solvate or derivative thereof.

18. (Original) The method of claim 9 further comprising administering to the patient a pharmaceutically effective amount of at least one agent selected from the group consisting of an antiviral agent, a chemokine receptor modulatory agent, a raft domain inhibitory agent, a cholesterol reducing agent, a protein prenylation reducing agent, a Rho-A GTPase inhibitor, and a glycosphingolipid reducing agent.

19. (Currently amended) The method of claim 17 ~~or claim 18~~, wherein in the one or more agents is admixed with a pharmaceutically acceptable carrier, binder, filler, vehicle, diluent, or excipient or any combination thereof.

20. (Currently amended) The method of ~~any one of claims 17 to 19~~ claim 17, wherein said antiviral agent is an addition salt selected from the group consisting of an acid addition salt, a metal addition salt, an ammonium salt, and a salt formed with an organic base.

21. (Currently amended) The method according to ~~any one of claims 17 to 20~~ claim 17, wherein said glycosphingolipid reducing agent is a compound selected from the group consisting of:

D-t-3',4'-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol,
D-t-4'-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol,
1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol,
pharmaceutically acceptable salts thereof, and mixtures thereof.

22. (Currently amended) The method according to ~~any one of claims 17 to 21~~ claim 17, wherein said antiviral agent is a compound selected from the group consisting of nucleosides, nucleotides, protease inhibitors, pyrimidinones, and pyridinones.

23. (Currently amended) The method according to ~~any one of claims 17 to 22~~ claim 17, wherein said raft domain inhibitory agent dissociates raft domains.

24. (Currently amended) The method according to ~~any one of claims 17 to 22~~ claim 17, wherein said raft domain inhibitory agent inhibits the formation of raft domains.

25. (Currently amended) The method according to ~~any one of claims 17 to 24~~ claim 17, wherein said chemokine receptor modulatory agent inhibits the formation of and/or dissociates membrane raft domains.

26. (Currently amended) The method according to ~~any one of claims 17 to 25~~ claim 17, wherein said Rho-A GTPase inhibitor is a statin.

27. (Currently amended) The method according to ~~any one of claims 17 to 26~~ claim 17, wherein the method further comprises separate, sequential or simultaneous administration of one or more of the agents.

28. (Original) A method of treatment of a mammal suffering from HIV, a retroviral infection genetically related to HIV, or AIDS by preventing the accumulation of HIV receptors in raft domains comprising providing a non-raft targeted mutant cytokine receptor.

29. (Original) The method according to Claim 28, wherein said mutant receptor binds HIV but does not enter into raft domains.